Sustained release aminopyridine composition
US11786514B2 · kind B2 · utility
0Cited by
20References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 22, 2022 |
| Grant date | Oct 17, 2023 |
| Priority date | — |
| Expiry date | Jun 22, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical composition which comprises therapeutically effective amount of a aminopyridine dispersed in a release matrix, including, for example, a composition that can be formulated into a stable, sustained-release oral dosage formulation, such as a tablet which provides, upon administration to a patient, a therapeutically effective plasma level of the aminopyridine for a period of at least 12 hours, preferably 24 hour or more and the use of the composition to treat various neurological diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.